BNP Paribas Financial Markets’s AVANIR PHARMACEUTICALS, INC CL A AVNR Stock Holding History

BNP Paribas Financial Markets’s Portfolio AVNR Stock Details AVNR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q4	–	Sell	-10,700	Closed	-$128K	–	4059
2014 Q3	$128K	Buy	10,700 +10,341	+2,881%	+$70.6K	﹤0.01%	2067
2014 Q2	$2.02K	Buy	+359	New	+$1.65K	﹤0.01%	3098
2014 Q1	–	Sell	-1,883	Closed	-$6.33K	–	4165
2013 Q4	$6.33K	Sell	1,883 -37,121	-95%	-$153K	﹤0.01%	2947
2013 Q3	$165K	Sell	39,004 -11,459	-23%	-$54.3K	﹤0.01%	2310
2013 Q2	$232K	Buy	+50,463	New	+$173K	﹤0.01%	2211

Other funds holding AVNR

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

WIC

Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

OAM

Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

BNP Paribas Financial Markets's AVNR Position: Q4 2014 in Review

BNP Paribas Financial Markets sold out of AVANIR PHARMACEUTICALS, INC CL A (AVNR) in Q4 2014, closing a stake of 10,700 shares — an estimated $128K sold.

BNP Paribas Financial Markets first reported a position in AVNR in Q2 2013 and held it in 5 quarters. The position peaked at $232K in Q2 2013. 166 funds tracked by Wall St. Rank hold AVNR as of Q4 2014.

BNP Paribas Financial Markets reported no remaining AVANIR PHARMACEUTICALS, INC CL A position as of Q4 2014 after selling out during the quarter.
BNP Paribas Financial Markets sold 10,700 AVANIR PHARMACEUTICALS, INC CL A shares in Q4 2014, an estimated $128K.
BNP Paribas Financial Markets first reported a position in AVANIR PHARMACEUTICALS, INC CL A in Q2 2013 and held it in 5 quarters.
BNP Paribas Financial Markets's AVANIR PHARMACEUTICALS, INC CL A position peaked at $232K in Q2 2013.
166 funds tracked by Wall St. Rank held AVANIR PHARMACEUTICALS, INC CL A as of Q4 2014.

Based on BNP Paribas Financial Markets's 13F filing for Q4 2014, filed 11 Feb 2015.